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Exacerbation of Granular Corneal Dystrophy Type 2 After
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Purpose: To report the outcome of unilateral small incision
lenticule extraction (SMILE) in a patient with granular corneal
dystrophy type 2 (GCD2).
Methods: Slit-lamp photography and Fourier domain optical
coherence tomography were used to document the clinical course
and appearance of the corneas in a patient with genetically
determined GCD2 who underwent unilateral SMILE in the
right eye.
Results: Slit-lamp examination of a 23-year-old woman revealed 2
faint opacities at the surgical interface approximately 2 months after
the SMILE procedure had been performed on her right eye. Nine and
3 typical GCD2 deposits located immediately beneath the Bowman
layer were observed in the right and left corneas, respectively. Over
time, the deposits at the interface increased in size, density, and
number in the right eye. Fourier domain optical coherence tomog-
raphy performed 33 months after the SMILE procedure revealed
deposits at the SMILE interface that were distinct from those located
immediately beneath the Bowman layer. The severity of disease
exacerbation was less in this patient than what is typically observed
in others who have undergone laser-assisted in situ keratomileusis or
photorefractive keratectomy.
Conclusions: SMILE is contraindicated in patients with GCD2, as
are other corneal refractive surgical procedures. This case highlights
the importance of genetic testing before the performance of
refractive corneal procedures—especially for patients with corneal
opacities on preoperative slit-lamp examination or a family history of
corneal disease compatible with that of a corneal dystrophy.
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Granular corneal dystrophy type 2 (GCD2) is anautosomal-dominant corneal stromal dystrophy caused
by a missense mutation in the transforming growth factor-
b–induced gene (TGFBI), which results in an Arg124His
mutation in the encoded protein.1 Trauma to the central cornea is
known to induce the transforming growth factor-b (TGF-b),2
which induces the TGFBI gene and the production of TGF-
b–induced protein (TGFBIp).3,4 Iatrogenic damage to the central
cornea caused by laser-assisted in situ keratomileusis (LASIK),
photorefractive keratectomy (PRK), and laser-assisted subepithe-
lial keratectomy has been reported to exacerbate corneal deposits
in patients with GCD2.5–9 Radial keratotomy has been reported
to exacerbate granular corneal dystrophy type 1 in 1 patient.10
Small incision lenticule extraction (SMILE) is a
relatively new refractive surgical procedure that uses a
femtosecond laser to create a stromal lenticule of the desired
shape within the corneal stroma. The lenticule is extracted
through a small (2.0–3.0 mm) incision, which causes less
damage to the corneal epithelium than LASIK, PRK, or laser-
assisted subepithelial keratectomy. We report the exacerba-
tion of GCD2 after SMILE for the first time, discuss the
mechanisms by which this might occur, and describe possible
strategies for its management.
CASE REPORT
A 23-year-old Korean woman was referred to Severance Eye
Hospital at Yonsei University for evaluation and management of
corneal opacities after unilateral SMILE, OD, which had been
performed elsewhere 2 months previously. She had no relevant
medical history. There was also no history of trauma or surgery,
except for the SMILE procedure in her right eye. There was a vague
family history of corneal disorders, but no definite diagnosis of GCD
in any family members.
Review of medical records obtained from the SMILE surgeon
revealed that her cornea was described as “within normal limits” at
the preoperative visit. Her manifest refraction before SMILE was
23.00 20.25 · 80 OD and 22.75 20.25 · 180 OS, yielding 20/20
corrected distance vision (CDVA) in both eyes. No genetic testing
was performed preoperatively.
On examination at our institution, uncorrected vision was 20/
20 OD and 20/70 OS. Manifest refraction was +0.50 0.00 ·180 OD
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and 22.25 20.50 · 180 OS. CDVA was 20/20 OD and 20/20 OS.
CDVA and manifest refraction for both eyes were unchanged at all
subsequent visits.
Slit-lamp examination revealed 9 small, faint deposits in the
anterior corneal stroma of the right eye immediately beneath the
Bowman layer (Fig. 1A). Two very faint deposits were also
observed at the SMILE interface by slit-lamp microscopy, but
these could not be documented photographically or with Fourier
domain optical coherence tomography (FD-OCT; RTvue-100,
Optovue Inc, Fremont, CA). The appearance of these deposits
suggested early exacerbation of GCD2. In the left cornea, 3
granular deposits were observed in the anterior stroma immediately
beneath the Bowman layer (Fig. 1B). The ocular examination was
otherwise unremarkable. Genetic testing confirmed heterozygosity
for GCD2.
Slit-lamp examination and FD-OCT performed 5 months after
SMILE revealed more prominent deposits at the SMILE interface in
the right eye and deposits beneath the Bowman layer in both eyes
similar to those commonly observed in GCD2 corneas that have not
undergone refractive surgery (Fig. 2).11 Interface deposits could not
be documented by FD-OCT.
From 8 to 15 months after SMILE, the size and number of
corneal deposits beneath the Bowman layer increased gradually in
the right eye, whereas only the size of the deposits increased in the
left eye (Fig. 3). At 15 months after SMILE, 1 deposit located at the
SMILE interface could be captured by photography, but not by FD-
OCT imaging (Fig. 3E, arrowhead).
Thirty-three months after SMILE, 3 deposits were observed
along the SMILE interface in the right cornea by slit-lamp
examination (Fig. 4A). The size and number of both interface and
subepithelial deposits had increased noticeably since the initial visit.
The left cornea, which served as an internal unoperated control,
showed 3 granular deposits that had increased slightly in size, but not
in number, since the initial visit. Subepithelial and interface deposits
were imaged simultaneously on 1 FD-OCT sagittal section (Figs. 4B,
C). One deposit can be seen in the anterior stroma immediately
beneath the Bowman layer, and the other can be seen at the SMILE
interface (Fig. 4C).
FIGURE 1. Corneal deposits seen at
the initial visit, 2 months after SMILE,
OD. A, Slit-lamp photograph show-
ing granular deposits in the anterior
stroma immediately beneath Bow-
man’s layer in the right eye (arrows).
Very small interface deposits were
seen by slit-lamp examination, but
these could not be documented
photographically. B, Slit-lamp pho-
tograph showing granular deposits in
the anterior stroma beneath Bow-
man’s layer in the left eye (arrows).
FIGURE 2. Corneal deposits 5
months after SMILE, OD. A, Slit-lamp
photograph showing granular
deposits in the right eye. B, FD-OCT
video image of the same eye. The
arrow points to the same deposit
shown in panels A and B. C, FD-OCT
image showing the anterior sub-epi-
thelial location of the deposit (arrow),
which is clearly separate from the
SMILE interface (arrowheads). The
distance measuring tool in panel C
indicates that the interface is 389 mm
from the corneal endothelium.
Kwak et al Cornea  Volume 40, Number 4, April 2021
520 | www.corneajrnl.com Copyright © 2021 The Author(s). Published by Wolters Kluwer Health, Inc.
To compare the location of deposits in this case with those
appearing after LASIK in patients with GCD2, we obtained the amputated
flap from a 40-year-old woman with GCD2 who had undergone LASIK
20 years previously and stained the specimen with Masson’s trichrome
stain. As can be seen, deposits are located beneath the Bowman layer and
adjacent to the flap internal surface of the amputated flap (Fig. 5), similar
to what we observed after SMILE (Fig. 4C).
This study followed the tenets of the Declaration of Helsinki
and was approved by the Severance Hospital Institutional Review
Board, Seoul, South Korea (4-2020-0600).
DISCUSSION
We report herein a patient with GCD2 in whom
corneal deposits appeared at the surgical interface 2
months after SMILE. These deposits increased in size,
density, and number through 33 months postoperatively.
Both the operative and unoperated eyes displayed sub-
epithelial granular deposits, typical of those seen in the
corneas of patients with GCD2 who have not undergone
corneal surgery.11 The number and size of these subepi-
thelial deposits increased more in the eye that had
undergone SMILE than in the opposite, unoperated eye.
Although increasing in severity, the interface deposits
were few in number and small in size, even 33 months
postoperatively, suggesting that exacerbation of GCD2 after
SMILE is not as severe as it is after other corneal refractive
surgical procedures.5,9,12 This conclusion may be premature,
however, because this is the first reported case of the results
of SMILE performed on a patient with GCD2, and other
factors might influence the phenotypic expression of the
GCD2 mutation, as discussed below.
Previous studies of eyes in which there was an
exacerbation of GCD2 after LASIK revealed that the
corneal deposits appear at the flap interface, as seen in
Figure 5, and increase in severity over time.8,13,14
We previously demonstrated by immunohistochemistry
that the interface deposits seen after LASIK contain
TGFBIp.14 Using scanning electron microscopy, we found
that these deposits adhere to exposed, cut edges of
collagen fibers, which are produced by LASIK,13 and we
hypothesize that GCD2 deposits at the SMILE interface
will be similarly localized.
Han et al15 reported a broad variation in the severity of
phenotypic expression of corneal deposits among patients with
heterozygous GCD2. Choi et al16 reported twofold differences
in the expression of 555 genes between primary cultured wild-
type and homozygous GCD2 corneal fibroblasts. They dem-
onstrated that primary cultured fibroblasts from individuals
FIGURE 3. Corneal deposits 8, 12,
and 15 months after SMILE, OD.
Panels A and B show deposits in the
right and left eyes, respectively, at 8
months. Panels C and D show
deposits in the right and left eyes,
respectively, at 12 months. Panels E
and F show deposits in the right and
left eyes, respectively, at 15 months.
One faint deposit in panel E (arrow-
head) is located at the interface, but
it could not be documented by FD-
OCT. All other deposits were located
in the anterior stroma immediately
beneath Bowman’s layer.
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who were heterozygous or homozygous for GCD2 were more
strongly adherent to collagen-I, collagen-IV, fibronectin, and
laminin in comparison to wild-type cells.16
Recent molecular studies showed that the features and
function of the mitochondria, as well as cellular oxidative
stress, were altered in cultured corneal fibroblasts expressing
FIGURE 4. Corneal deposits 33
months after SMILE, OD. A, Slit-
lamp photograph showing granular
deposits in the right eye in the
anterior stroma (arrow) and at the
SMILE interface (arrowhead). B, FD-
OCT video image of the same eye.
The arrow and arrowhead point to
deposits that are similarly marked in
panel A. C, FD-OCT image showing
that one of these deposits is located
in the anterior sub-epithelial stroma
(arrow), and the other is located at
the SMILE interface (arrowhead).
The distance measuring tool in C
indicates that there is 354 mm
between the SMILE interface, where
the deposit is located, and the cor-
neal endothelium (this newly
formed and more centrally located
interface deposit is different from the
deposits seen in Fig. 2).
FIGURE 5. Corneal deposits after
LASIK in a patient with GCD2. A,
Slit-lamp photograph showing
numerous granular deposits in the
anterior stroma. B, FD-OCT image
showing a deposit in the anterior
stroma (arrowhead) and deposits at
the LASIK flap interface (arrows). C,
Histological section of the ampu-
tated LASIK flap showing a deposit
at the anterior stroma (arrowhead)
and deposits at the LASIK flap inter-
face (arrows; Masson’s trichrome
stain; original magnification ·200).
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mutant TGFBIp.17,18 Choi et al19,20 demonstrated that TGFBIp
causes a delay in autophagic clearance because of impaired
lysosomal function in cultured GCD2 corneal fibroblasts.
Based on these studies, we hypothesize that the phenotypic
expression of the GCD2 Arg124His mutation might be
modified by other influential genes. Future studies will be
necessary to determine whether the relatively mild exacerba-
tion of disease in our case might be related to the characteristics
of genes other than TGFBI or to the fact that SMILE is
inherently less likely to exacerbate GCD2 than LASIK.15,21
TGF-b, which plays an essential role in wound healing
via its pleotropic effects on cell proliferation, cell differentia-
tion, extracellular matrix production, and immune modula-
tion,22,23 activates TGFBI, leading to the production of
TGFBIp.24 Exacerbation of corneal deposits in patients with
GCD2 is undoubtedly related to the role that TGF-b plays in
wound healing.3 The corneal epithelium produces more TGF-b
than stromal keratocytes.25–27 The SMILE procedure causes
less epithelial and subepithelial trauma than LASIK. This may
help to explain why exacerbation of CGD2 might be less
severe after SMILE than it is after LASIK.
Currently, there are no universally effective long-term
strategies to manage visually significant exacerbations of GCD2
after SMILE. Phototherapeutic keratectomy (PTK) can post-
pone keratoplasty in patients with GCD2 whose corneal
deposits are exacerbated after LASIK, although the deposits
eventually recur. PTK performed on the surface of the
remaining posterior stroma after amputation of the flap was
reported to be superior to PTK performed with flap retention for
visual acuity, recurrence, and complications.28 PTK performed
with flap retention involves excimer ablation on both the
posterior surface of the flap and the surface of the posterior
remaining stroma. Amputation of the cornea anterior to the
SMILE interface followed by PTK on the surface of the
remaining stroma may be a reasonable treatment strategy if
deposits become visually significant. A 40 to 60 mm PTK might
be sufficient to remove most visually significant deposits from
the remaining corneal stroma.28
Another strategy might be to perform a second SMILE to
remove the additional stromal tissue containing opaque
deposits from both sides of the interface. This strategy is
theoretically feasible, given that conventional SMILE has high
accuracy and predictability in creating incisions at the intended
depth, with a minimum lenticule thickness at its edge of 15 mm
(range 10–30 mm) in a clear cornea.29,30 Additional accumu-
lation of deposits beneath the Bowman layer and near the
interface may, however, impair transmission of laser energy,
resulting in inaccurate cuts if SMILE is repeated. This and
other procedures that involve removal of the opacities by ex-
cimer laser ablation will undoubtedly be temporary because we
anticipate further accumulation of deposits postoperatively.
Further studies are needed to determine the safety and efficacy
of these potential treatments for managing visually significant
exacerbations of GCD2 after SMILE.
In summary, we report the appearance of corneal deposits
at the interface after SMILE in a patient with GCD2. The
severity of these deposits was less than those typically seen after
LASIK. Further studies will be required to determine whether
this difference in severity is due to reduced epithelial trauma
from SMILE compared with that of LASIK, the effect of
modulating genes, or other factors. This case highlights the
importance of genetic testing before the performance of
refractive corneal procedures—especially for patients with
corneal opacities on preoperative slit-lamp examination or a
family history of corneal disease compatible with that of a
corneal dystrophy. We conclude that SMILE is contraindicated
in patients with GCD2, just like LASIK and PRK are contra-
indicated in these patients.
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